Amgen (NASDAQ:AMGN) Rating Lowered to Hold at Wall Street Zen

Amgen (NASDAQ:AMGN) was downgraded by investment analysts at Wall Street Zen from a “buy” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other equities research analysts have also recently commented on AMGN. Rothschild & Co Redburn raised their target price on Amgen from $180.00 to $200.00 and gave the stock a “sell” rating in a research note on Wednesday. Sanford C. Bernstein cut Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price on the stock. in a report on Tuesday, January 20th. Barclays initiated coverage on Amgen in a research report on Friday. They issued an “equal weight” rating and a $350.00 price target for the company. TD Cowen restated a “buy” rating on shares of Amgen in a research note on Wednesday, February 4th. Finally, Guggenheim upped their price target on shares of Amgen from $305.00 to $347.00 and gave the company a “neutral” rating in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have issued a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and a consensus price target of $351.76.

Amgen Stock Down 0.2%

Shares of NASDAQ AMGN opened at $374.75 on Friday. Amgen has a 52-week low of $261.43 and a 52-week high of $385.12. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. The company’s 50 day moving average price is $343.21 and its 200-day moving average price is $316.20. The company has a market capitalization of $202.02 billion, a P/E ratio of 26.34, a price-to-earnings-growth ratio of 3.80 and a beta of 0.46.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business had revenue of $9.87 billion for the quarter, compared to analyst estimates of $9.46 billion. During the same quarter in the previous year, the business earned $5.31 earnings per share. Amgen’s revenue for the quarter was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts forecast that Amgen will post 20.62 earnings per share for the current year.

Institutional Trading of Amgen

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. High Note Wealth LLC raised its stake in shares of Amgen by 5.8% during the fourth quarter. High Note Wealth LLC now owns 508 shares of the medical research company’s stock valued at $166,000 after acquiring an additional 28 shares during the last quarter. TAGStone Capital Inc. grew its holdings in shares of Amgen by 0.7% during the 4th quarter. TAGStone Capital Inc. now owns 4,129 shares of the medical research company’s stock worth $1,351,000 after acquiring an additional 28 shares during the period. Verus Capital Partners LLC raised its position in shares of Amgen by 2.3% in the 4th quarter. Verus Capital Partners LLC now owns 1,231 shares of the medical research company’s stock worth $403,000 after acquiring an additional 28 shares in the last quarter. Destination Wealth Management boosted its holdings in Amgen by 2.1% in the fourth quarter. Destination Wealth Management now owns 1,393 shares of the medical research company’s stock worth $456,000 after acquiring an additional 29 shares in the last quarter. Finally, West Family Investments Inc. grew its stake in shares of Amgen by 1.1% in the third quarter. West Family Investments Inc. now owns 2,760 shares of the medical research company’s stock worth $779,000 after acquiring an additional 30 shares during the last quarter. Institutional investors own 76.50% of the company’s stock.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Rothschild & Co Redburn says Amgen’s stock price is expected to rise — a bullish analyst view that could support upside if reiterated or joined by others. Amgen (NASDAQ:AMGN) Stock Price Expected to Rise, Rothschild & Co Redburn Analyst Says
• Neutral Sentiment: Amgen priced $4.0 billion of senior unsecured notes across multiple maturities — this increases debt but provides liquidity; impact depends on use of proceeds (buybacks, M&A, refinancing). Investors should watch tenor and coupon details to assess financing cost and leverage effects. Amgen Prices $4 Billion Senior Unsecured Notes Offering
• Neutral Sentiment: Amgen has been a “trending” ticker on sites like Zacks and Yahoo — heightened attention can lift liquidity and volatility but is not a directional fundamental catalyst by itself. Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
• Neutral Sentiment: “Here’s What the Street is Saying” roundups summarize mixed analyst commentary — useful for context but check individual firm views for conviction and PTs. Here’s What the Street is Saying About Amgen Inc. (AMGN)
• Neutral Sentiment: Short-interest data reported for mid-February appears to show 0 shares (NaN/incomplete) and a 0.0 days-to-cover metric — likely a reporting glitch; no reliable evidence here of a significant short squeeze or increase in bearish positioning.
• Negative Sentiment: Barclays initiated coverage with an “equal-weight” rating and a $350 price target, implying roughly a mid-single-digit downside from recent levels — this new coverage (and PT below the current price) is a near-term headwind for sentiment. Barclays initiates coverage of Amgen (AMGN) with equal-weight recommendation

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.